Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zilovertamab vedotin by Merck for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Zilovertamab vedotin by Merck for Ureter Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Ureter Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Urethral Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Urethral Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Bladder Cancer: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Zilovertamab vedotin by Merck for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Zilovertamab vedotin by Merck for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Zilovertamab vedotin by Merck for Non-Hodgkin Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase I for Lymphoma. According to GlobalData, Phase I...
Zilovertamab vedotin by Merck for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
Zilovertamab vedotin by Merck for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
Zilovertamab vedotin by Merck for Follicular Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Mantle Cell Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
Zilovertamab vedotin by Merck for Solid Tumor: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
Zilovertamab vedotin by Merck for Neuroblastoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...
Zilovertamab vedotin by Merck for Burkitt Lymphoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
Zilovertamab vedotin by Merck for Ewing Sarcoma: Likelihood of Approval
Zilovertamab vedotin is under clinical development by Merck and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merck's Zilovertamab vedotin?
Zilovertamab vedotin is a monoclonal antibody conjugated commercialized by Merck, with a leading Phase III program in Diffuse Large B-Cell...
Risk adjusted net present value: What is the current valuation of Merck's Zilovertamab vedotin?
Zilovertamab vedotin is a monoclonal antibody conjugated commercialized by Merck, with a leading Phase III program in Diffuse Large B-Cell...